CN115806620B - Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof - Google Patents
Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof Download PDFInfo
- Publication number
- CN115806620B CN115806620B CN202211554200.2A CN202211554200A CN115806620B CN 115806620 B CN115806620 B CN 115806620B CN 202211554200 A CN202211554200 A CN 202211554200A CN 115806620 B CN115806620 B CN 115806620B
- Authority
- CN
- China
- Prior art keywords
- protein
- monoclonal antibody
- cell strain
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 title claims abstract description 54
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 26
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000003119 immunoblot Methods 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 230000014509 gene expression Effects 0.000 abstract description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 11
- 239000012634 fragment Substances 0.000 abstract description 11
- 239000000427 antigen Substances 0.000 abstract description 10
- 102000036639 antigens Human genes 0.000 abstract description 10
- 108091007433 antigens Proteins 0.000 abstract description 10
- 238000001514 detection method Methods 0.000 abstract description 7
- 230000003053 immunization Effects 0.000 abstract description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 238000005457 optimization Methods 0.000 abstract description 5
- 102100036407 Thioredoxin Human genes 0.000 abstract description 4
- 108020004705 Codon Proteins 0.000 abstract description 3
- 241000672609 Escherichia coli BL21 Species 0.000 abstract description 3
- 230000007910 cell fusion Effects 0.000 abstract description 3
- 238000013115 immunohistochemical detection Methods 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 2
- 102000052147 human WFDC2 Human genes 0.000 abstract 1
- 210000002955 secretory cell Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000010186 staining Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000016517 ovarian serous tumor Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010004433 Benign ovarian tumour Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000037700 Mucinous adenocarcinoma of ovary Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 201000007428 ovarian mucinous adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The application relates to a monoclonal antibody capable of recognizing human HE4 antigen, a secretory cell strain, a preparation method thereof and application thereof in immunodetection. According to the technical scheme, 31-124 amino acids of HE4 protein are selected as antigen peptides, codon optimization is carried out, the gene fragment suitable for expression in escherichia coli BL21 is formed, and finally the obtained recombinant protein comprises a TRX protein tag, an HE4 protein fragment and a histidine protein tag. The recombinant protein is used for immunizing a mouse, and cell fusion, screening and subcloning are carried out to obtain a mouse hybridoma cell strain 3G10 which can efficiently secrete the HE4 protein monoclonal antibody and the HE4 protein monoclonal antibody secreted by the cell strain. The antibody obtained by the scheme has high specificity and sensitivity, can specifically identify cells expressing HE4 protein, and is suitable for immunological detection, in particular immunohistochemical detection.
Description
Technical Field
The application relates to the field of biomedical engineering, in particular to a monoclonal antibody for resisting HE4 protein, a cell strain, a preparation method and application thereof.
Background
Human epididymal protein (HE 4) is a secreted protein, and its gene cDNA was first extracted from the distal end of epididymal epithelium by Kirchhoff in 1991, and was solidly named human epididymal protein. Because of the highly conserved characteristic WAP domain in the molecular structure, the HE4 gene is also known as WAP-4-disulfide core domain 2 (WFDC 2), also known as WFDC2.WAP domain is a conserved sequence of approximately 50 amino acids containing 8 cysteines with 4 disulfide bonds (4-DSC) as core region, and the encoded protein has high homology with extracellular protease inhibitor, but HE4 has not been found to have the effect of inhibiting protease. The HE4 gene is located on human chromosome 20q12-13.1, has a total length of about 12kb and consists of 5 exons and 4 introns, and has various shearing forms and encodes small molecule secretion proteins. HE4 is expressed in the genital tract, breast, respiratory tract, kidney distal tubule, colon, salivary glands of human normal females, but is expressed low or not in normal ovarian tissue, whereas the positive expression rate in ovarian tissue is correlated with the tissue type of ovarian cancer, with serous ovarian cancer being the highest. Studies have shown that HE4 may inhibit cell proliferation in vitro through PI3K/AKT signaling pathways, and from the premise that HE4 may play a protective role by inhibiting cancer cell proliferation.
The method for detecting the expression condition of HE4 in different ovarian tissues by using an immunohistochemical method shows that HE4 is highly expressed in high-grade serous ovarian cancer and has statistical significance with the expression difference between normal ovarian tissues and benign ovarian tumor tissues. The positive expression rate of HE4 increases with the progress of clinical stage, and the difference between the III-IV stage and the I-II stage has statistical significance.
Disclosure of Invention
The inventor provides a monoclonal antibody of anti-HE 4 protein, wherein the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4; the amino acid sequence of the monoclonal antibody light chain variable region is the amino acid sequence shown in SEQ ID NO. 5.
Further, the DNA sequence of the heavy chain variable region of the monoclonal antibody is the nucleotide sequence shown as SEQ ID NO.2, and the DNA sequence of the light chain variable region of the monoclonal antibody is the nucleotide sequence shown as SEQ ID NO. 3.
Further, the monoclonal antibody specifically recognizes HE4 protein.
Further, the monoclonal antibody is a mouse IgG1 kappa subtype monoclonal antibody.
Further, the monoclonal antibody is produced by a hybridoma cell strain with a preservation number of CGMCCNO 21972.
The inventor also provides a preparation method of the anti-HE 4 protein monoclonal antibody, wherein an antigen used for immunizing mice is recombinant protein, and the recombinant protein is expressed by escherichia coli in a recombination way and comprises a TRX protein tag, an HE4 protein fragment and a histidine protein tag.
Further, the HE4 protein fragment is an amino acid fragment from 31 st to 124 th positions of HE4 protein, and the amino acid sequence of the HE4 protein fragment is the amino acid sequence shown in SEQ ID NO. 1.
The inventor also provides a hybridoma cell strain secreting HE4 protein resistant molecules, wherein the cell strain is a mouse hybridoma cell strain 3G10, and the cell strain is preserved in China general microbiological culture collection center (CGMCCNO) 21972 at 2021, 3 months and 24 days, and is provided at the national institute of microbiological culture, national institute of sciences, 1, 3, beijing, chaoyang, north.
The inventor also provides an HE4 protein immunodetection reagent, which contains an amino acid sequence of a heavy chain variable region, wherein the amino acid sequence is shown as SEQ ID NO. 4; the monoclonal antibody of the HE4 protein with the amino acid sequence shown in SEQ ID NO.5 as the light chain variable region is taken as an effective component.
Further, the immunodetection includes immunohistochemistry, immunoblotting and enzyme-linked immunosorbent assay.
Compared with the prior art, the application has the following beneficial technical effects: according to the technical scheme, 31-124 amino acids of HE4 protein are selected as antigen peptides, codon optimization is carried out, the gene fragment suitable for expression in escherichia coli BL21 is formed, and finally the obtained recombinant protein comprises a TRX protein tag, an HE4 protein fragment and a histidine protein tag. The recombinant protein is used for immunizing a mouse, and cell fusion, screening and subcloning are carried out to obtain a mouse hybridoma cell strain 3G10 which is used for efficiently secreting the HE4 protein monoclonal antibody and the HE4 protein monoclonal antibody secreted by the cell strain. The antibody obtained by the scheme has high specificity and sensitivity, can specifically identify cells expressing HE4 protein, and is suitable for immunological detection, in particular immunohistochemical detection.
Drawings
FIG. 1 is a diagram of purified pectin from recombinant HE4 proteins fused with histidine tag of example 1, wherein M represents Marker;1 is a supernatant sample; 2 is the post-ultrasound pellet sample.
FIG. 2 is a graph comparing results of immunohistochemical staining of ovarian serous tumors; wherein the left part is HE4 secreted by 3G10, and the right part is commercial HE4.
Detailed Description
In order to describe the possible application scenarios, technical principles, practical embodiments, and the like of the present application in detail, the following description is made with reference to the specific embodiments and the accompanying drawings. The embodiments described herein are only for more clearly illustrating the technical aspects of the present application, and thus are only exemplary and not intended to limit the scope of the present application.
Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment may be included in at least one embodiment of the application. The appearances of the phrase "in various places in the specification are not necessarily all referring to the same embodiment, nor are they particularly limited to independence or relevance from other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the technical features mentioned in each embodiment may be combined in any manner to form a corresponding implementable technical solution.
Unless defined otherwise, technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present application pertains; the use of related terms herein is for the purpose of describing particular embodiments only and is not intended to limit the application.
In the description of the present application, the term "and/or" is a representation for describing a logical relationship between objects, which means that three relationships may exist, for example a and/or B, representing: there are three cases, a, B, and both a and B. In addition, the character "/" herein generally indicates that the front-to-back associated object is an "or" logical relationship.
In the present application, terms such as "first" and "second" are used merely to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual number, order, or sequence of such entities or operations.
Without further limitation, the use of the terms "comprising," "including," "having," or other like terms in this specification is intended to cover a non-exclusive inclusion, such that a process, method, or article of manufacture that comprises a list of elements does not include additional elements but may include other elements not expressly listed or inherent to such process, method, or article of manufacture.
As in the understanding of "review guidelines," the expressions "greater than", "less than", "exceeding" and the like are understood to exclude this number in the present application; the expressions "above", "below", "within" and the like are understood to include this number. Furthermore, in the description of embodiments of the present application, the meaning of "a plurality of" is two or more (including two), and similarly, the expression "a plurality of" is also to be understood as such, for example, "a plurality of" and the like, unless specifically defined otherwise.
EXAMPLE 1 preparation of recombinant HE4 protein fragments
1. Gene optimization and synthesis
HE4 selects the 31-124 amino acid protein fragment according to the protein sequence with accession number Q14508 in Uniprot database, and directly optimizes the gene fragment suitable for expression in escherichia coli BL 21. Respectively adding at the 5 'and 3' ends of the gene during PCR BamHI And an XhoI cleavage site.
The PCR product was recovered after agarose gel electrophoresis separation, bamHI and XhoI digestion were performed on the recovered fusion protein gene and plasmid vector pET30a for expression, respectively, and the recovered product was again electrophoretically recovered and ligated with T4DNA ligase. And (4) transforming the connection product into escherichia coli competent cells BL21, picking up clones on a flat plate, and carrying out bacterial liquid PCR identification. Clones positive to the PCR result were selected for sequencing analysis and clones with the correct sequence were used.
The selection of different antigens for immunization may produce antibodies with different binding characteristics, which molecule may have multiple variants due to variable cleavage at the same time, ultimately resulting in different antibodies with different recognition capacities and patterns for antigen expressing cells. HE4 molecules are analyzed according to published sequences, according to the structure, antigenicity, hydrophilicity and hydrophobicity of constituent amino acids on cell membranes and secondary structure, a region suitable for soluble expression and having good immunogenicity is selected for recombinant expression, 31-124 amino acid residues of HE4 are selected for codon optimization, and the molecular weight is about 42kDa. And obtaining the HE4 protein by utilizing a prokaryotic expression gene sequence through sequence optimization design. The recombinant immunogen consists of HE4 protein fragment with antigenicity and protein tag for recombinant protein purification, wherein the protein tag is TRX and HIS.
2. Protein expression and purification
The overnight bacteria cultured by single colony are transferred to 100mLLB culture medium according to the proportion of 1:100, kanamycin with the final concentration of 10 mug/mL is added, the culture medium is subjected to shaking culture at 37 ℃ until the OD600 is 0.6-0.8, IPTG with the concentration of 0.5mmol/L is added, the culture medium is subjected to shaking culture at 37 ℃ for 2 hours, and the bacteria are harvested by ultrasonic disruption. The recombinant protein has a histidine tag, and affinity purification of the protein is performed using a nickel column. Elution was performed with 300mmol/L imidazole and detection was performed by SDSPAGE separation.
FIG. 1 is a diagram of purified pectin from recombinant HE4 proteins fused to histidine tags. The protein concentration is 2.3mg/mL, and can be used for animal immunization and the requirements of antibody screening and identification.
Example 2 establishment of hybridoma cell lines
1. Immunization
The recombinant protein of example 1 was emulsified with Freund's complete adjuvant (Sigma, F5881) and immunized with 4-6 week old female ICR mice (purchased from Peking Vitre Liwa laboratory animal technologies Co., ltd.) at a dose of 20 μg/mouse by abdominal subcutaneous injection at 6 points per mouse. Once every 14 days, the antigen was emulsified with Freund's incomplete adjuvant (Sigma, F5506) at a dose of 20 μg/dose. The polyclonal antibody titer of the anti-immunogen in the serum of the mice was detected by indirect ELISA (wavelength 450 nm) 7 days after the 3 rd booster immunization, the mice with the highest titer were immunized by tail vein injection, and the antigens were uniformly mixed with physiological saline at a dose of 20 mug/mouse.
2. Cell fusion
Sterile preparation of immune-up to-standard mouse spleen cell suspension, mixing with mouse myeloma cell sp2/0 (ATCC NumberCRL-8287) at a ratio of 5:1, centrifuging at 1500rpm for 5min. The supernatant was discarded, the tube was placed in a 37℃water bath, 1ml of PEG1500 (Roche Co.) was slowly added over 1 minute, and the cells were agitated. After standing in warm water for 1min, 10ml of serum-free IMDM (Sigma Co.) was added, mixed well, centrifuged at 1000rpm for 5min. After the supernatant was discarded, 10ml of serum (PAA company) was added and the cells were carefully blown up, and 5ml of thymocytes mixed with 10xHAT (Sigma company) were added and mixed. 25ml of semisolid medium containing 2.1% nitrocellulose (Sigma Co.) was added and mixed well, and then poured into 20 cell culture dishes uniformly. Placing the cell culture dish into a wet box, placing 5% CO at 37deg.C 2 Culturing in an incubator.
3. Cloning and ELISA screening positive hybridoma cells
The size and density of the cloned cell mass are moderate 7 days after fusion, round, solid and large clone mass is sucked into a 96-hole culture plate which is prepared with culture medium in advance under a dissecting lens, and is put into 5% CO at 37 DEG C 2 Culturing in an incubator. After 3 days, the cell mass was approximately 2/3 of the floor space, and 100. Mu.L of the supernatant was screened by ELISA using the immunogen and the synthetic polypeptide, respectively. Positive clones were completely changed and 200. Mu.L of complete medium containing feeder cells and 1% HT (Sigma Co.) was added. Two days later, a second ELISA screening was performed and positive clones were transferred to 24-well plates in which medium (containing feeder cells and HT) was prepared in advance. Five days later, 100 μl of the supernatant was subjected to a third ELISA screening, and positive clones were successively transferred into 6-well plates and cell culture flasks for expansion culture and frozen storage. EXAMPLE 3 preparation of monoclonal antibodies by ascites Induction
1. Ascites preparation
Cells in logarithmic growth phase were washed and suspended in serum-free medium and counted approximately 5X 10 5 1ml. Suspended cells were intraperitoneally injected into mice previously sensitized with paraffin oil. Ascites collection was started after 7 days. The ascites removed was centrifuged at 4000rpm at 4℃for 10min. Carefully aspirate the middleThe ascites is collected in a centrifuge tube and stored at 4 ℃ or-20 ℃.
2. Purification of monoclonal antibodies
Antibodies were purified from ascites fluid using HiTraprProteinAFF (GE company) affinity chromatography as described. SDS-PAGE gel was used to identify purity and concentration was determined by the Bradford method. Purified antibodies were stored at-20 ℃.
EXAMPLE 4 characterization of monoclonal antibodies
1. Subclass identification
The coated sheep anti-mouse IgG (Abies sinensis Biotechnology Co., ltd., beijing) was diluted to 0.5. Mu.g/ml with 100mM PBS (pH 7.4), 100. Mu.l/well, 4℃overnight. The liquid was emptied and washed 3 times with PBS containing 0.05% Tween (PBS-T), 200. Mu.l of blocking solution (PBS containing 2% BSA and 3% sucrose) was added to each well and incubated for 1h at 37 ℃. The liquid was emptied and washed 3 times with PBS-T. 0.1ml of hybridoma supernatant was added to each well and incubated at 37℃for 1h. The liquid was emptied and washed 3 times with PBS-T. With blocking liquid 1: HRP-labeled goat anti-mouse (κ, λ) antibody or 1:2000 dilution of HRP-labeled goat anti-mouse (IgM, igG1, igG2a, igG2b, igG3, igA) antibodies (southern Biotech) 0.1ml per well were added to the appropriate wells and incubated for 1h at 37 ℃. The liquid was emptied and washed 3 times with PBS-T. Mu.l of a mixture containing 0.15% ABTS (southern Biotech) and 0.03% H was added to each well 2 O 2 The reaction was developed with a citric acid buffer (pH 4.0) and the OD at 405nm was measured in 10-20 min.
The results showed that the monoclonal antibody of the present application was an IgG1 kappa-type murine monoclonal antibody.
2. Affinity constant determination
HE4 recombinant protein prepared in example 1 was coated at a concentration of 2. Mu.g/ml, 100. Mu.l/well, coated overnight at 4℃and washed 3 times with PBS-T. Mu.l of blocking solution was added to each well and blocked at 37℃for 2h, and PBS-T was washed 3 times. The monoclonal antibodies purified in example 3, from 1:200 beginning 2-fold gradient dilution, leaving 1 well blank for control, incubating for 1h at 37℃and washing 3 times with PBS-T. HRP-labeled goat anti-mouse secondary antibody 1: diluted 20000, incubated at 37℃for 1h in 100. Mu.l/well and washed 3 times with PBS-T. Mu.l of 0.1% TMB (Sigma Co.) and 0.03% H were added to each well 2 O 2 Is developed for 10min in citric acid-phosphoric acid buffer solution, and 50 mu.l of 0.5M sulfur is addedThe acid solution terminated the reaction. The absorbance at a wavelength of 450nm was measured with a microplate reader. Drawing a curve of OD value corresponding to dilution factor of antibody, finding out dilution factor A corresponding to half of maximum binding OD value, and calculating affinity constant of the antibody to 1.92×10 by using the following formula 9 。
Monoclonal antibody reaction specificity and application effect
The HE4 recombinant protein prepared in example 1 was used to detect the recognition specificity of the monoclonal antibody of the application by immunoblotting, and 12% polyacrylamide gel electrophoresis was performed. Gel protein bands were transferred onto PVDF membranes (Millipore Corp.) in a Bio-Rad electrotransfer system according to conventional methods. The membranes were placed in TBS-T blocking solution containing 5% nonfat milk powder overnight at 4 ℃. Monoclonal antibodies (1:1000 dilution) to the antibodies secreted by the 41B1 hybridoma were added and incubated overnight at 4 ℃. After washing the membrane with TBS-T, 1: sheep anti-mouse secondary antibody (fir gold bridge biotechnology limited in beijing) diluted at 5000 was incubated for 1 hour at room temperature. The membrane was again washed with TBST, ECL hypersensitivity developing solution (Beijing pride Gene technologies Co., ltd.) was added, and chemiluminescent image data was collected using a ChemiDocMP multicolor fluorescence imaging system (Bio-Rad).
Example 5 determination of variable region sequence of antibodies
Taking fresh hybridoma cells, taking supernatant, performing antigen binding characteristic verification, confirming that cell strain used for cloning can indeed secrete required antibody, and centrifuging and collecting 10 after confirming the result 6 The above hybridoma cells. Trizol method is used for extracting total RNA of hybridoma cells, 9 mu L of total RNA is taken, 2.5 mu oligo (dT) 12-18primer (10 mM) and 5 mu L dNTPs are added, and the mixture is uniformly mixed, and the mixture is kept at 70 ℃ for 5 minutes and then placed on ice for 5 minutes, or the denaturation operation is carried out according to the reverse transcriptase used. Subsequently, 5. Mu.LRTbuffer (5X), 2.5. Mu.LDTT (0.1M) and 1. Mu.L reverse transcriptase were added and reacted at 42℃for 1 hour. The reaction was terminated by incubating at 70℃for 15 minutes, and the obtained cDNA was stored at-20 ℃. The first strand cDNA obtained was amplified by PCR, and each primer was added to a 50. Mu.L reaction system25pmol of primers for amplifying the heavy chain variable region and the light chain variable region were designed and synthesized according to the sequence of the murine monoclonal antibody primer in the book of recombinant antibody (scientific Press, 2005) mainly edited by Shen Beifen.
The rest dNTPs and buffer solution are added according to the conventional method, and finally 1 mu L of cDNA template and 1U of hot start Taq DNA polymerase are added. The PCR amplification procedure was set to 94℃for 40 seconds, 52℃for 40 seconds, 72℃for 40 seconds, 20 to 25 cycles were performed, and finally 72℃was extended for 3 minutes, and the product was allowed to stand by at 4℃or directly electrophoresed. The 20 mu LPCR product is taken for electrophoresis analysis, separated on 1.5% agarose gel, the length of the light chain (kappa light chain) is 320-340bp, the length of the heavy chain is 340-370bp, the specific product in the region is recovered by cutting gel, and cloned to a T vector or an expression vector for sequencing.
EXAMPLE 6 immunohistochemical tissue chip staining and identification
Chip preparation process
HE section staining was performed on each sample to determine tumor sites. The tissue chip was fabricated using a full-automatic tissue chip instrument from 3 DHISTECH. Putting the prepared tissue chip wax block into a wax block manufacturing mould, putting the mould into a 68 ℃ oven for 10 minutes to enable the tissue core and the wax of the receptor wax block to be fused into a whole, then slightly taking out the mould from the oven, cooling the paraffin in a semi-fused state for about 30 minutes at room temperature, putting the mould into a-20 ℃ refrigerator for 6 minutes, taking out the tissue chip wax block from the mould, and slicing or putting the mould into a 4 ℃ refrigerator for preservation for later use. After trimming, continuous slicing is carried out, the thickness is set to be 3 mu m, the continuous slicing is floated in 40% alcohol, the continuous slicing is naturally unfolded, then the separated slices are transferred into warm water with the temperature of 50 ℃ for 30 seconds, the slices are pasted on a glass slide which is treated by polylysine, the prepared tissue chips are placed into an oven with the temperature of 68 ℃ for baking the slices for 2 hours, and the tissue chips are taken out, cooled at room temperature and placed into a refrigerator with the temperature of minus 4 ℃ for preservation.
IHC staining and analysis
Conventional xylenes were dewaxed 3 times for 6 minutes each, hydrated in 100%, 95%, 85% gradient ethanol for 3 minutes each, and finally rinsed with tap water. Antigen retrieval was performed and the sections were then placed in a wet box and rinsed 3 x 3 min in PBS. Dropwise adding 3%H 2 O 2 Incubate for 10min, rinse with PBS for 3 x 3 min. The sections were spun dry, incubated for 1 hour at room temperature (25 ℃) with primary antibody diluted in the appropriate ratio (the dilution ratio of the antibody was designed according to the concentration of the antibody for the first time), washed 3X 3 minutes with PBS, incubated for 15-30 minutes with secondary antibody at room temperature, washed 3X 3 minutes with PBS, spun off the PBS, and developed for 3-10 minutes with freshly prepared DAB developing solution. Hematoxylin counterstain for 25 seconds and PBS returns to blue for 30 seconds. Sequentially dehydrating according to an alcohol gradient of 85% (3 minutes) to 95% (3 minutes) to 100% (3 minutes), and finally making xylene transparent for 3 minutes, and sealing the gel.
Immunohistochemical staining results were divided into: positive and negative. Positive expression must be positive at the cell and tissue specific antigenic sites. Under the conditions of clear tissue staining distribution and accurate cell positioning, the staining results are further divided according to the difference of staining intensity, and the specific steps are as follows:
1. the sample is weak positive; marked as "+";
2. the sample is moderately positive; marked as "++";
3. the sample was highly positive; marked as' ++ ".
4. The sample was negative, labeled "-".
Third, data statistics
1. Tumor tissue chip detection results:
the present antibody HE4 (3G 10) and the commercial antibody HE4 (OTI 1B 9) were synchronously detected in 32 cases of ovarian mucinous adenocarcinoma and 36 cases of ovarian serous tumors, and the detection results were compared.
The immunohistochemical results for HE4 were counted. The whole test process adopts double-blind design, and the statistical result is as follows:
the result shows that the anti-HE 4 protein monoclonal antibody secreted by the 3G10 cell strain has accurate staining and positioning, clear staining, no nonspecific staining and clean background. In immunohistochemical detection, the positive rate was comparable to that of commercially available antibodies, but the positive intensity was higher than that of commercially available antibodies. The HE4 secreted by the 3G10 cell strain is higher in sensitivity, and false negative results are effectively avoided.
FIG. 2 is a comparison of results of immunohistochemical staining of ovarian serous tumors (left HE4 secreted by 3G10, right commercially available HE 4).
2. Normal tissue chip detection results:
the normal tissue chip comprises 30 normal tissue samples, wherein the normal tissue samples are mainly selected from fresh and timely fixed surgical specimens; each tissue included 3 different case samples. The 30 normal tissues include: brain, heart, cerebellum, esophagus, adrenal gland, stomach, ovary, small intestine, pancreas, colorectal, parathyroid, liver, pituitary, salivary gland, testis, kidney, thyroid, prostate, breast, uterus, spleen, bladder, tonsils, skeletal muscle, thymus (young children), skin, bone marrow, peripheral nerves, lung, mesothelial cells.
The antibody (3G 10) and the commercial antibody are synchronously detected on a normal tissue chip, and the detection results of yin and yang are consistent, which shows that the specificity of the antibody in normal tissues is equivalent to that of the commercial antibody.
Finally, it should be noted that, although the embodiments have been described in the text and the drawings, the scope of the application is not limited thereby. The technical scheme generated by replacing or modifying the equivalent structure or equivalent flow by utilizing the content recorded in the text and the drawings of the specification based on the essential idea of the application, and the technical scheme of the embodiment directly or indirectly implemented in other related technical fields are included in the patent protection scope of the application.
Claims (8)
1. A monoclonal antibody against HE4 protein, characterized in that the amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID No. 4; the amino acid sequence of the monoclonal antibody light chain variable region is the amino acid sequence shown in SEQ ID NO. 5.
2. The monoclonal antibody according to claim 1, wherein the DNA sequence encoding the heavy chain variable region of the monoclonal antibody is the nucleotide sequence shown in SEQ ID No.2 and the DNA sequence encoding the light chain variable region of the monoclonal antibody is the nucleotide sequence shown in SEQ ID No. 3.
3. The monoclonal antibody of claim 1, wherein the monoclonal antibody specifically recognizes HE4 protein.
4. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a mouse IgG1 kappa subtype monoclonal antibody.
5. A monoclonal antibody against HE4 protein is produced by hybridoma cell strain with collection number of CGMCC NO 21972.
6. A hybridoma cell strain secreting HE4 protein resisting molecules, wherein the cell strain is a mouse hybridoma cell strain 3G10, and the cell strain is preserved in China general microbiological culture Collection center with the preservation number of: CGMCC NO 21972.
7. An HE4 protein immunodetection reagent, characterized in that it contains the monoclonal antibody against HE4 protein of claim 1 as an active ingredient.
8. The immunoassay reagent of claim 7, wherein said immunoassay comprises immunohistochemistry, immunoblotting and enzyme-linked immunoassay.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211554200.2A CN115806620B (en) | 2022-12-06 | 2022-12-06 | Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211554200.2A CN115806620B (en) | 2022-12-06 | 2022-12-06 | Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115806620A CN115806620A (en) | 2023-03-17 |
CN115806620B true CN115806620B (en) | 2023-12-05 |
Family
ID=85485051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211554200.2A Active CN115806620B (en) | 2022-12-06 | 2022-12-06 | Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115806620B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101949937A (en) * | 2010-08-20 | 2011-01-19 | 大连美亿德生物科技有限公司 | Oophoroma tumor marker HE4 time-resolved fluoroimmunoassay detection kit |
CN103374067A (en) * | 2012-04-26 | 2013-10-30 | 清泓生物技术(上海)有限公司 | Method for preparing human epididymis protein 4 (HE4) recombinant protein in mammalian cell |
CN113072642A (en) * | 2021-04-25 | 2021-07-06 | 福州迈新生物技术开发有限公司 | Monoclonal antibody of anti-OCT 3/4 protein and cell strain, preparation method and application thereof |
-
2022
- 2022-12-06 CN CN202211554200.2A patent/CN115806620B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101949937A (en) * | 2010-08-20 | 2011-01-19 | 大连美亿德生物科技有限公司 | Oophoroma tumor marker HE4 time-resolved fluoroimmunoassay detection kit |
CN103374067A (en) * | 2012-04-26 | 2013-10-30 | 清泓生物技术(上海)有限公司 | Method for preparing human epididymis protein 4 (HE4) recombinant protein in mammalian cell |
CN113072642A (en) * | 2021-04-25 | 2021-07-06 | 福州迈新生物技术开发有限公司 | Monoclonal antibody of anti-OCT 3/4 protein and cell strain, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115806620A (en) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112940118B (en) | Monoclonal antibody of anti-CK 8 protein, cell strain, preparation method and application thereof | |
CN113045667B (en) | anti-IDO 1 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113265003B (en) | anti-TdT protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113045652B (en) | anti-DOG 1 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN112940133B (en) | Monoclonal antibody of anti-ATRX protein, cell strain, preparation method and application thereof | |
CN113278070B (en) | anti-CK 17 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113072642B (en) | anti-OCT 3/4 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN108659125B (en) | Monoclonal antibody of anti-helicobacter pylori protein, cell strain, preparation method and application thereof | |
CN113061184B (en) | anti-CK 7 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113061186B (en) | Monoclonal antibody of anti CA125 protein, cell strain, preparation method and application thereof | |
CN113105547B (en) | anti-CD 5 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113087793B (en) | anti-CK 14 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113583120B (en) | Monoclonal antibody against CK20 protein, cell strain, preparation method and application thereof | |
CN117946276B (en) | Anti-MCM 2 protein monoclonal antibody, preparation method and application thereof | |
CN113087794B (en) | Monoclonal antibody for resisting HNF1 beta protein, cell strain, preparation method and application thereof | |
CN116120437B (en) | anti-HBsAg protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN116178537A (en) | anti-Calretinin protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113735971B (en) | anti-CK 18 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN116120436B (en) | anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113845592B (en) | anti-CK 5/6 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN115806620B (en) | Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof | |
CN115850468B (en) | Monoclonal antibody of anti-TBX 19 protein, cell strain, preparation method and application thereof | |
CN112940125A (en) | anti-VISTA protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113234158A (en) | anti-TIM 3 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN116903735B (en) | anti-TTF-1 protein monoclonal antibody and cell strain, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |